解码VEXAS综合征:对病原和临床管理的新兴见解
Martina Fiumara1,2, Corrado Campochiaro2,3, Raffaella Molteni2,4
1San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute.
Current opinion in rheumatology
|November 1, 2025
概括
维克萨斯综合征是一种体质的UBA1突变驱动疾病,涉及炎症性造血细胞,这些细胞损害了正常的血细胞发育. 目前的指导方针提供了管理VEXAS的策略,改善了患者的治疗结果.
科学领域:
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
- 遗传学 是一个遗传学.
背景情况:
- 维克萨斯 (VEXAS) 综合征 (真空,E1酶,X链接,自身炎症,体质) 是一种成人发病的自身炎症性疾病.
- 它的特征是具有体质UBA1基因突变的亲炎性造血细胞的克隆主导.
研究的目的:
- 审查和综合了解VEXAS综合征病变的最新进展.
- 讨论VEXAS综合征的当前临床管理策略.
主要方法:
- 文献综述综合了最近的发现.
- 分子机制分析和临床指导方针.
主要成果:
- 维克萨斯病变发生涉及炎症和UBA1突变造血细胞的克隆主导之间的相互作用.
- 突变细胞创造了一个炎症环境,损害了野生类型的血液形成,并表现出支持生存的途径.
- 最近的国际指导方针提供了基于证据的建议,用于管理炎症和血液学特征.
结论:
- 通过剖析炎症和克隆生存的分子驱动因素,了解VEXAS病理生物学正在进步.
- 目前的治疗策略旨在抵消疾病进展并改善患者的治疗结果.
- 未来的研究将使VEXAS综合征的更精确,机制驱动的治疗成为可能.
相关概念视频
Esophageal Varices-II: Clinical Features and Management
334
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
334
Aneurysm II: Clinical Manifestations and Diagnostic Studies
176
Thoracic, aortic arch and abdominal aneurysms are significant vascular conditions that can present with various clinical manifestations and lead to serious complications. Understanding these manifestations and the appropriate diagnostic studies is essential for effective management and treatment.Thoracic Aortic AneurysmsThoracic aortic aneurysms often remain asymptomatic until they reach a size that impinges on adjacent structures. They typically cause deep, diffuse chest pain that radiates to...
176
Atherosclerosis III: Management
290
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
290
Cystic Fibrosis: Pathogenesis
674
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
674
Barrett Esophagus-II: Clinical Manifestations and Management
726
Individuals with Barrett's esophagus are often asymptomatic, but they may experience symptoms commonly associated with GERD, such as heartburn and acid regurgitation. Additional symptoms can include difficulty swallowing, chest pain, unintentional weight loss, blood in the stool (which may appear black, tarry, or bloody), and episodes of vomiting.
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
726
Cystic Fibrosis: Management
434
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
434


